Skip to main content

Table 1 Characteristics of healthy controls (HC), benign adenoma (BA) patients, and colorectal cancer (CRC) patients

From: Thromboelastography (TEG) parameters as potential predictors of malignancy and tumor progression in colorectal cancer

 

Before matching

After matching

Variable

HC

Pa

BA

Pb

(CRC)

Pc

Pd

HC + BA

CRC

Pe

No. of cases

115

/

43

/

387

/

/

140

140

/

Age (years)

59.0 (50.0, 65.0)

0.077*

62.0 (55.0, 69.0)

0.206*

65.0 (59.0, 72.0)

< 0.001*

< 0.001*

62 (55.68)

61 (52.67)

0.277^

Sex (male) (n, %)

53 (46.1)

0.828^

24 (55.8)

1.000^

232 (59.9)

0.025^

0.031^

77 (55.0)

76 (54.3)

0.904^

Life style

 Smoking (n, %)

10 (8.7)

0.513^

7 (16.3)

1.000^

80 (20.7)

0.010^

0.012^

17 (12.1)

19 (13.6)

0.721^

 Drinking (n, %)

10 (8.7)

0.989^

6 (14.0)

1.000^

67 (17.3)

0.073^

0.076^

16 (11.4)

19 (13.6)

0.588^

Medical history

 Hypertension (n, %)

/

/

19 (44.2)

/

146 (37.7)

/

0.409^

19 (13.6)

16 (11.4)

0.588^

 Hyperlipidemia (n, %)

/

/

12 (27.9)

/

49 (12.7)

/

0.007^

12 (8.6)

7 (5.0)

0.235^

 Diabetes (n, %)

/

/

6 (14.0)

/

48 (12.4)

/

0.771^

6 (4.3)

6 (4.3)

1.000^

 Coronary heart disease (n, %)

/

/

0 (0.0)

/

10 (2.6)

/

0.608^

0 (0)

0 (0)

/

Laboratory parameters

 Hb (g/L)

141.0 (132.0, 150.0)

0.032*

133.0 (124.0, 145.0)

0.007*

126.0 (108.0, 137.0)

< 0.001*

< 0.001*

139.5 (130.0, 149.0)

125.0 (107.5, 136.0)

< 0.001#

 PLT (× 109/L)

209.5 (190.0, 237.0)

0.932*

206.5 (153.0, 236.0)

0.022*

224.0 (183.0, 272.0)

0.054*

0.004*

208.5 (181.0, 236.0)

229.0 (187.0, 276.5)

0.001#

 PT (s)

11.4 (11.1, 11.9)

1.000*

11.5 (11.1, 11.9)

0.052*

11.8 (11.3, 12.4)

< 0.001*

< 0.001*

11.4 (11.1, 11.9)

12.0 (11.4, 12.6)

< 0.001#

 APTT (s)

31.4 (29.5, 32.9)

1.000*

30.6 (28.7, 32.8)

0.731*

30.3 (28.6, 32.3)

0.002*

0.003*

31.3 (29.1 32.9)

30.2 (29.0 32.3)

0.051#

 TT (s)

14.4 (13.7, 15.0)

1.000*

14.9 (13.9, 15.4)

1.000*

14.4 (13.5, 15.3)

1.000*

0.420*

14.5 (13.7, 15.1)

14.5 (13.8, 15.3)

0.679#

 Fg (g/L)

3.5 (3.1, 4.0)

1.000*

3.7 (3.1, 4.1)

0.026*

4.1 (3.4, 5.0)

< 0.001*

< 0.001*

3.6 (3.2, 4.1)

4.1 (3.3, 4.7)

< 0.001#

 D-dimer (μg/L)

90.0 (59.0, 131.0)

0.045*

120.0 (70.0, 180.0)

0.121*

148.0 (89.0, 315.0)

< 0.001*

< 0.001*

94.5 (60.5, 137.5)

131.0 (85.0, 289.0)

< 0.001#

 CEA (μg/L)

1.4 (0.9, 2.3)

0.662*

1.7 (1.3, 2.7)

0.023*

3.0 (1.6, 6.3)

< 0.001*

< 0.001*

1.5 (0.9, 2.3)

2.7 (1.4, 5.3)

< 0.001#

 CA19-9 (U/mL)

5.9 (4.0, 10.7)

1.000*

7.2 (5.0, 10.9)

0.126*

10.5 (5.2, 23.8)

< 0.001*

< 0.001*

6.4 (4.3, 10.9)

9.0 (5.0, 19.6)

< 0.001#

TEG parameters

 R (min)

6.7 (5.8, 7.7)

1.000*

6.9 (6.1, 7.5)

0.051*

6.3 (5.5, 7.1)

0.0370*

0.006*

6.7 (5.8, 7.7)

6.2 (5.7, 7.2)

0.013#

 K (min)

1.9 (1.8, 2.2)

1.000*

1.9 (1.7, 2.2)

< 0.001*

1.6 (1.3, 1.9)

< 0.001*

< 0.001*

1.9 (1.8, 2.2)

1.7 (1.4, 2.0)

< 0.001#

 α-Angle (deg)

63.8 (61.1, 66.2)

1.000*

63.7 (61.5, 66.0)

< 0.001*

67.4 (63.9, 70.6)

< 0.001*

< 0.001*

63.8 (61.2, 66.2)

66.9 (62.9, 70.2)

< 0.001#

 MA (mm)

59.8 (56.9, 62.9)

1.000*

60.8 (57.1, 63.0)

< 0.001*

63.5 (60.4, 67.3)

< 0.001*

< 0.001*

60.2 (56.9, 63.0)

62.9 (60.3, 66.2)

< 0.001#

  1. The bold in the table means statistically significant (P < 0.05). aP, compared between HC and BA groups, was adjusted by Bonferroni correction (before propensity score matching). bP, compared between BA and CRC groups, was adjusted by Bonferroni correction (before propensity score matching). cP, compared between HC and CRC groups, was adjusted by Bonferroni correction (before propensity score matching). dP, compared across all the groups (before propensity score matching). eP, compared between HC + BA and CRC groups (after matching). *P, tested by Kruskal–Wallis test; ^P, tested by chi-square test; #P, tested by Mann–Whitney U-test
  2. Abbreviations: HC Healthy controls, BA Benign adenoma patients, CRC Colorectal cancer patients, Hb Hemoglobin, PLT Platelet, Fg Fibrinogen, PT Prothrombin time, APTT Activated partial thromboplastin time, TT Thrombin time, CEA Carcinoma embryonic antigen, CA19-9 Carbohydrate antigen 19–9